These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25966424)

  • 21. p53 Mutations in human cholangiocarcinoma: a review.
    Khan SA; Thomas HC; Toledano MB; Cox IJ; Taylor-Robinson SD
    Liver Int; 2005 Aug; 25(4):704-16. PubMed ID: 15998419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma.
    Chiang NJ; Shan YS; Hung WC; Chen LT
    Int J Biochem Cell Biol; 2015 Oct; 67():110-4. PubMed ID: 26100596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of molecular genetic factors in the development of cholangiocellular carcinoma].
    Chulkova SV; Loginov VI; Podluzhnyi DV; Egorova AV; Syskova AY; Semichev DG; Gladilina IA; Kudashkin NE
    Arkh Patol; 2022; 84(3):76-83. PubMed ID: 35639847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
    Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
    Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The molecular pathogenesis of cholangiocarcinoma.
    Berthiaume EP; Wands J
    Semin Liver Dis; 2004 May; 24(2):127-37. PubMed ID: 15192786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholangiocarcinoma: new insights into disease pathogenesis and biology.
    Braconi C; Patel T
    Infect Dis Clin North Am; 2010 Dec; 24(4):871-84, vii. PubMed ID: 20937455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of microRNA-203 in cholangiocarcinoma.
    Li J; Gao B; Huang Z; Duan T; Li D; Zhang S; Zhao Y; Liu L; Wang Q; Chen Z; Cheng K
    Int J Clin Exp Pathol; 2015; 8(8):9512-6. PubMed ID: 26464713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular aspects of cholangiocarcinoma.
    Kiguchi K
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
    Borad MJ; Gores GJ; Roberts LR
    Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholangiolocellular Carcinoma With "Ductal Plate Malformation" Pattern May Be Characterized by ARID1A Genetic Alterations.
    Sasaki M; Sato Y; Nakanuma Y
    Am J Surg Pathol; 2019 Mar; 43(3):352-360. PubMed ID: 30520820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer.
    Nakagawa H; Hayata Y; Yamada T; Kawamura S; Suzuki N; Koike K
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29895797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
    Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
    J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
    [No Abstract]   [Full Text] [Related]  

  • 35. Role of molecular genetics in the clinical management of cholangiocarcinoma.
    Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
    ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of epigenetic alterations in cholangiocarcinoma.
    Tischoff I; Wittekind C; Tannapfel A
    J Hepatobiliary Pancreat Surg; 2006; 13(4):274-9. PubMed ID: 16858537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
    Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
    Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
    Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
    Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetics of hepatobiliary carcinogenesis.
    Nault JC; Zucman-Rossi J
    Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
    Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.